WallStreetZenWallStreetZen

NASDAQ: BLTE
Belite Bio Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for BLTE

Based on 2 analysts offering 12 month price targets for Belite Bio Inc.
Min Forecast
$57.00+54.05%
Avg Forecast
$57.50+55.41%
Max Forecast
$58.00+56.76%

Should I buy or sell BLTE stock?

Based on 2 analysts offering ratings for Belite Bio Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BLTE stock forecasts and price targets.

BLTE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 5%
96
BuyInitiates Coverage On$58.00+56.76%2022-08-01
Benchmark
Bottom 2%
2
Strong BuyInitiates Coverage On$57.00+54.05%2022-07-01

1 of 1

Forecast return on equity

Is BLTE forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is BLTE forecast to generate an efficient return on assets?
Company
-76.17%
Industry
-5.22%
BLTE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BLTE earnings per share forecast

What is BLTE's earnings per share in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$0.58

BLTE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RZLT$2.82$14.40+410.64%Strong Buy
ETNB$4.95$27.50+455.56%Strong Buy
ABVC$0.91$6.25+584.56%Strong Buy
LEXX$2.47N/AN/A
PRTG$6.81$22.00+223.05%Buy

Belite Bio Stock Forecast FAQ

Is Belite Bio Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BLTE) stock is to Strong Buy BLTE stock.

Out of 2 analysts, 1 (50%) are recommending BLTE as a Strong Buy, 1 (50%) are recommending BLTE as a Buy, 0 (0%) are recommending BLTE as a Hold, 0 (0%) are recommending BLTE as a Sell, and 0 (0%) are recommending BLTE as a Strong Sell.

If you're new to stock investing, here's how to buy Belite Bio stock.

What is BLTE's earnings growth forecast for 2022-2023?

(NASDAQ: BLTE) Belite Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 18.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 46.52%.

Belite Bio's earnings in 2022 is -$9,666,000.On average, 1 Wall Street analyst forecast BLTE's earnings for 2022 to be -$10,120,033, with the lowest BLTE earnings forecast at -$10,120,033, and the highest BLTE earnings forecast at -$10,120,033.

In 2023, BLTE is forecast to generate -$13,975,284 in earnings, with the lowest earnings forecast at -$13,975,284 and the highest earnings forecast at -$13,975,284.

What is BLTE's forecast return on equity (ROE) for 2022-2023?

(NASDAQ: BLTE) forecast ROE is N/A, which is considered weak.

What is BLTE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BLTE price target, the average BLTE price target is $57.50, with the highest BLTE stock price forecast at $58.00 and the lowest BLTE stock price forecast at $57.00.

On average, Wall Street analysts predict that Belite Bio's share price could reach $57.50 by Aug 1, 2023. The average Belite Bio stock price prediction forecasts a potential upside of 55.41% from the current BLTE share price of $37.00.

What is BLTE's Earnings Per Share (EPS) forecast for 2022-2023?

(NASDAQ: BLTE) Belite Bio's current Earnings Per Share (EPS) is -$1.01. On average, analysts forecast that BLTE's EPS will be -$0.42 for 2022, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at -$0.42. In 2023, BLTE's EPS is forecast to hit -$0.58 (min: -$0.58, max: -$0.58).

What is BLTE's forecast return on assets (ROA) for 2022-2023?

(NASDAQ: BLTE) forecast ROA is -76.17%, which is lower than the forecast US Biotechnology industry average of -5.22%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.